Recent News

• 09.17.2025 - Oruka Therapeutics Announces $180 Million Private Placement
• 09.17.2025 - Oruka Therapeutics Announces $180 Million Private Placement
• 09.17.2025 - Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001
• 09.17.2025 - Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001
• 08.21.2025 - Kaveri Pohlman
• 08.21.2025 - Kaveri Pohlman
• 08.11.2025 - Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 08.11.2025 - Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 07.21.2025 - Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September
• 07.21.2025 - Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September

Recent Filings

• 08.11.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.11.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 07.17.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 07.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.01.2025 - 3 Initial statement of beneficial ownership of securities
• 07.01.2025 - 8-K Current report
• 06.03.2025 - 8-K Current report
• 06.03.2025 - 4 Statement of changes in beneficial ownership of securities